1. Pharmindex. http://pharmindex.pl

2. Charakterystyka Produktu Leczniczego ClotrimazolumGSK.

3. Viswanatha B, Sumatha D, Vijayashree MS. Otomycosis in immunocompetent and immunocompromised patients: comparative study and literature review. Ear Nose Throat J 2012; 91(3): 114-121.

4. Satish HS, Viswanatha B, Manjuladevi M. A Clinical Study of Otomycosis. IOSR J Dental Med Sci 2013; 5(2): 57-62.

5. Khan F, Muhammad R, Khan MR. i wsp. Efficacy of topical clotrimazole in treatment of otomycosis. J Ayub Med Coll Abbottabad 2013; 25(1-2): 78-80.

6. Kolling WM., McPherson TB, McJunkin JL. The use of extemporaneously compounded 1% tetracaine to improve adherence with clotrimazole 1% topical solution in the treatment of ear infection: a case report. Am J Otolaryngol 2013; 34(6): 757-758.

7. Kuthan R. Kandydoza pochwy i sromu. Lek w Polsce 2014; 4: 32-41.

8. Stanowisko Zespołu Ekspertów Polskiego Towarzystwa Ginekologicznego dotyczące etiopatogenezy i leczenia nawrotowej postaci drożdżakowego zapalenia pochwy i sromu, Ginekol Pol 2011; 82: 869-873.

9. Mayser P, Hort W, Pflieger-Bruss S.: Anogenitale Pilzerkrankungen, Hautarzt 2005; 56(6): 531–539.

10. Rodin P, Kolator B. Carriage of yeasts on the penis, Br Med J 1976, 1, 6018, 123–24.

11. Fakjian N, Hunter S., Cole GW i wsp. An argument for circumcision revention of balanitis in the adult, Arch Dermatol 1990; 126(8): 1046–1047.

12. Edwards SK, Bunker C, Ziller F i wsp. 2013 European guideline for the management of balanoposthitis, Int J STD AIDS 2014, 25, 615–626.

13. Porche D. Tinea pedis: a common male foot problem. J Nurse Prac 2006; 2(3): 152–153.

14. Crevits B, Picoto A, Staberg B i wsp. Comparison of efficacy and safety of oral fluconazole and topical clotrimazole in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidiasis. Curr Ther Res 1998; 59 (7): 503–510.

15. Borhade V, Pathak S, Sharma S i wsp. Clotrimazole nanoemulsion for malaria chemotherapy. Part II: Stability assessment, in vivo pharmacodynamic evaluations and toxicological studies. Int J Pharm 2012; 431 (1–2): 149–160.

16. Brugnara C, Gee B, Armsby CC i wsp. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1996; 97(5): 1227–1234.

17. Penso J, Beitner R. Detachment of glycolytic enzymes from cytoskeleton of Lewis lung carcinoma and colon adenocarcinoma cells induced by clotrimazole and its correlation to cell viability and morphology. Mol Genet Metabol 2002; 76(3): 181–188.

18. Coelho RG, Calaça Ide C, Celestrini Dde M i wsp. Clotrimazole disrupts glycolysis in human breast cancer without affecting non-tumoral tissues. Mol Gen Metabol 2011; 103(4): 394-398.